1. Medicine

Category Archives: Medicine

ChyawanprashOne Herbal Medicine,Many Health Benefits-Dr. Mukesh Sharma(Ayurveda Expert) – Video

Posted on by


ChyawanprashOne Herbal Medicine,Many Health Benefits-Dr. Mukesh Sharma(Ayurveda Expert)
http://www.pragyatv.com/ To get wellness updates and advise subscribe to PragyaWellnessTV: http://www.youtube.com/subscription_center?add_user=PragyaWellnessTV ...

By: Pragya T

See the article here:

ChyawanprashOne Herbal Medicine,Many Health Benefits-Dr. Mukesh Sharma(Ayurveda Expert) - Video

Institute of Medicine President to Speak at the University of Louisville Dec. 10

Posted on by

Contact Information

Available for logged-in reporters only

Newswise LOUISVILLE, Ky. The president of the Institute of Medicine of the National Academies will present the 2014 Leonard Leight Lecture at the University of Louisville.

Victor J. Dzau, M.D., will speak at noon, Wednesday, Dec. 10, at Kornhauser Library Auditorium on the UofL Health Sciences Campus. Admission is free.

Dzau will discuss Molecular Approaches to Cardiac Regeneration, an area of research being explored at UofL. Roberto Bolli, M.D., director of UofLs Institute of Molecular Cardiology, and his colleagues have successfully shown in 19 patients who previously suffered a heart attack that their stem cells, after processing, can be re-infused back into the damaged heart muscle and improve its function.

The Leonard Leight Lecture is presented annually by the Division of Cardiovascular Medicine, also headed by Bolli, in the Department of Medicine at UofLs School of Medicine. For 30 years until 1996, Leight was a practicing cardiologist in Louisville and played a major role in developing cardiology services and bringing innovative treatment modalities in heart disease to Louisville.

The Leonard Leight Lecture series was established in 1994 and is made possible by gifts from Dr. and Mrs. Kurt Ackermann and Medical Center Cardiologists to the Jewish Hospital & St. Marys Foundation.

About Victor Dzau

Dzau assumed the presidency of the Institute of Medicine July 1 after having served as chancellor for health affairs at Duke University, president and CEO for Duke University Health System, and the James B. Duke Professor, Duke University School of Medicine. He was elected to the IOM in 1988 and served on several leadership committees prior to being named president.

He has made a significant impact on medicine through his seminal research in cardiovascular medicine and genetics, his pioneering work in the discipline of vascular medicine, and recently his leadership in health care innovation.

See original here:

Institute of Medicine President to Speak at the University of Louisville Dec. 10

Medicine Coupons Donated to Mainstream Housing, Inc by Charles Myrick Of American Consultants RX – Video

Posted on by


Medicine Coupons Donated to Mainstream Housing, Inc by Charles Myrick Of American Consultants RX
http://www.charleslmyrick.com -Charity begins at home....Identifying individuals and organizations giving back to others in need. "Copyright Disclaimer Under Section 107 of the Copyright Act...

By: Charles Myrick

Link:

Medicine Coupons Donated to Mainstream Housing, Inc by Charles Myrick Of American Consultants RX - Video

New technique to decellularize tissues for tissue engineering and regenerative medicine – Video

Posted on by


New technique to decellularize tissues for tissue engineering and regenerative medicine
New technique to decellularize tissues for tissue engineering and regenerative medicine. Subscribe this channel to watch more motivational, inspirational, valuable and informative videos to...

By: Health Mind Body Spirit

More:

New technique to decellularize tissues for tissue engineering and regenerative medicine - Video

The Central Dogma of Alternative Medicine – Dr. David Gorski – Skepticon 7 – Video

Posted on by


The Central Dogma of Alternative Medicine - Dr. David Gorski - Skepticon 7
gorskon http://www.sciencebasedmedicine.org/author/david-gorski/ Skepticon.org This talk was part of Skepticon 7, November 21-23 in Springfield, MO. 100% of the ad revenue from this video...

By: HamboneProductions

View original post here:

The Central Dogma of Alternative Medicine - Dr. David Gorski - Skepticon 7 - Video

Prevention of ACL Injuries in Female Athletes – Nemours Center for Sports Medicine – Video

Posted on by


Prevention of ACL Injuries in Female Athletes - Nemours Center for Sports Medicine
Anterior Cruciate Ligament (ACL) injuries in young female athletes have increased 400 percent in the last few years. At The Nemours Center for Sports Medicine, we are committed to the treatment...

By: Nemours

The rest is here:

Prevention of ACL Injuries in Female Athletes - Nemours Center for Sports Medicine - Video

Shaman Black Raven and His Mate, Medicine Woman Blue Fairy (Semi-Relief Sand Sculpture) – Video

Posted on by


Shaman Black Raven and His Mate, Medicine Woman Blue Fairy (Semi-Relief Sand Sculpture)
Duane specializes in his own unique variation of the traditional Native American sand sculpture found in the American Southwest. His style builds up the sculpture on portions of the artwork...

By: Artistic Conquests by Duane L. West

See the rest here:

Shaman Black Raven and His Mate, Medicine Woman Blue Fairy (Semi-Relief Sand Sculpture) - Video

Improving access to medicine in developing countries

Posted on by

Pharmaceutical industry doing more to improve access to medicine in developing countries; performance on some aspects lags

Amsterdam, the Netherlands: The worlds leading pharmaceutical companies are doing more to improve access to medicine in developing countries, with a raft of new initiatives, scale-ups and innovations over the last two years. However, the industry struggles to perform well in some practices that matter, according to the 2014 Access to Medicine Index, published Monday.

GSK tops the Index for the fourth time. This is driven by robust performance across most areas, with several innovative practices. Novo Nordisk has made the most progress, improving in five of the seven areas the Index focuses on. This has resulted in a remarkable leap from 6th to 2nd place. Sanofi and Pfizer fell down the ranking most significantly. After sharpening what and how we measure, we are now able to draw a much clearer picture of the industrys strengths, weaknesses, progress and struggles, and what it takes to be a leader in access to medicine, said Wim Leereveld, founder and CEO of the Access to Medicine Index. No company is in the top five in all areas we analyse, but the leaders tend to perform well across most of them, even though they differ in their focus. Top performers innovate constantly, and usually have to innovate in several areas to maintain their position.

The Access to Medicine Index is an independent initiative that ranks the worlds leading pharmaceutical companies according to what they are doing for the millions of people in developing countries who do not have reliable access to medicine. It scores companies across seven areas of activity considered key to improving access to medicine, including product research and development, to what extent they facilitate or resist efforts to create generic versions of their drugs, how they approach pricing in developing countries, lobbying activities and marketing ethics.

Companies that have the biggest market presence are not necessarily at the top of the Index. We found that four companies currently produce 50 percent of all the relevant products. However, they are scattered across the Index, said Jayasree K. Iyer, Head of Research at the Access to Medicine Index. This means that what defines where companies rank has less to do with how many relevant products they have, than with what they do with their products and expertise.

Progress on several fronts The industry has stepped up its efforts on several fronts. For instance, it is paying more attention to socioeconomic factors, increasingly tailoring prices within countries. Since 2012, the number of products in the pipeline appropriate for developing countries has grown by 47. More companies are experimenting with innovative access-oriented business models. Companies are granting more licences to developing country companies to make and distribute generic versions of their medicines. Meanwhile, policies and activities to improve access to medicine continue to get better organised.

Performance weak in two areas However, progress is uneven across the areas of activity that matter, with the industry struggling to perform well in two important areas. Firstly, nearly all companies (18) have been the subject of settlements or judgements regarding breaches in ethical marketing, bribery or corruption standards or competition laws in the last two years. During the period of analysis there were high-profile allegations of corrupt practices against several companies operating in China. The case against GSK, one of those companies, was settled after the period of analysis, and therefore did not affect its score in the 2014 Index. Secondly, companies remain conservative in their disclosure of where patents are active and when they will expire information that is very useful to medicine procurers and generics manufacturers.

Research and development analysis Pharmaceutical company research and development (R&D) is a crucial element of enhancing access to medicine. The 2014 Index reveals how concentrated the relevant R&D is. Just five companies are developing 54% of the 327 products in the pipeline. All disease classes are being targeted, but more than half of the products under development target just five diseases: lower respiratory infections, diabetes, hepatitis, HIV/AIDS and malaria. About 36% of the pipeline targets non-communicable diseases, which are becoming increasingly important in developing countries. But plans to make these products available in developing countries are limited. Pricing strategies for them are also limited, and lag behind those for many communicable diseases. More than half of the companies are developing child-size medicines, as liquids, chewable tablets, child-appropriate doses, or new formulations. Since the 2012 Index, at least 30 products from the pipeline, for 11 diseases relevant to developing countries, have come to the market. These include:

A new type of pill for multi-drug resistant tuberculosis that is the first new drug for the disease in 40 years. (Johnson & Johnson) A ground-breaking pill that can cure hepatitis C, which is a high-burden disease in developing countries. The company has issued licences allowing distribution of generic versions of the drug in more than 91 developing countries. (Gilead) Our company report cards identify a tailored path for each company to follow in order to maximise its opportunities for improving access to medicine. They all address access issues in different ways, but our analysis shows that all companies can do more, Leereveld said.

END

View post:

Improving access to medicine in developing countries

Isokinetic London Conference 2015 – Football Medicine Strategies Trailer – Video

Posted on by


Isokinetic London Conference 2015 - Football Medicine Strategies Trailer
Isokinetic Medical Group welcomes you to London and to the XXIV edition of the Conference. Throughout the years this event has become the meeting point of the international Football Medicine...

By: GruppoMedico Isokinetic

Link:

Isokinetic London Conference 2015 - Football Medicine Strategies Trailer - Video


  1. Medicine